<?xml version='1.0' encoding='utf-8'?>
<document id="26401256"><sentence text="Effects of ranolazine on exercise capacity, right ventricular indices, and hemodynamic characteristics in pulmonary arterial hypertension: a pilot study."><entity charOffset="11-21" id="DDI-PubMed.26401256.s1.e0" text="ranolazine" /></sentence><sentence text="Ranolazine, a late inward sodium current and fatty acid oxidation inhibitor, may improve right ventricular (RV) function in pulmonary arterial hypertension (PAH); however, the safety and efficacy of ranolazine in humans with PAH is unknown"><entity charOffset="0-10" id="DDI-PubMed.26401256.s2.e0" text="Ranolazine" /><entity charOffset="45-55" id="DDI-PubMed.26401256.s2.e1" text="fatty acid" /><entity charOffset="199-209" id="DDI-PubMed.26401256.s2.e2" text="ranolazine" /><entity charOffset="225-228" id="DDI-PubMed.26401256.s2.e3" text="PAH" /><entity charOffset="157-159" id="DDI-PubMed.26401256.s2.e4" text="PAH" /><pair ddi="false" e1="DDI-PubMed.26401256.s2.e0" e2="DDI-PubMed.26401256.s2.e0" /><pair ddi="false" e1="DDI-PubMed.26401256.s2.e0" e2="DDI-PubMed.26401256.s2.e1" /><pair ddi="false" e1="DDI-PubMed.26401256.s2.e0" e2="DDI-PubMed.26401256.s2.e4" /><pair ddi="false" e1="DDI-PubMed.26401256.s2.e0" e2="DDI-PubMed.26401256.s2.e2" /><pair ddi="false" e1="DDI-PubMed.26401256.s2.e0" e2="DDI-PubMed.26401256.s2.e3" /><pair ddi="false" e1="DDI-PubMed.26401256.s2.e1" e2="DDI-PubMed.26401256.s2.e1" /><pair ddi="false" e1="DDI-PubMed.26401256.s2.e1" e2="DDI-PubMed.26401256.s2.e4" /><pair ddi="false" e1="DDI-PubMed.26401256.s2.e1" e2="DDI-PubMed.26401256.s2.e2" /><pair ddi="false" e1="DDI-PubMed.26401256.s2.e1" e2="DDI-PubMed.26401256.s2.e3" /><pair ddi="false" e1="DDI-PubMed.26401256.s2.e4" e2="DDI-PubMed.26401256.s2.e4" /><pair ddi="false" e1="DDI-PubMed.26401256.s2.e4" e2="DDI-PubMed.26401256.s2.e2" /><pair ddi="false" e1="DDI-PubMed.26401256.s2.e4" e2="DDI-PubMed.26401256.s2.e3" /><pair ddi="false" e1="DDI-PubMed.26401256.s2.e2" e2="DDI-PubMed.26401256.s2.e2" /><pair ddi="false" e1="DDI-PubMed.26401256.s2.e2" e2="DDI-PubMed.26401256.s2.e3" /></sentence><sentence text=" Therefore, we sought to (1) determine whether ranolazine is safe and well tolerated in PAH and (2) explore ranolazine's effect on symptoms, exercise capacity, RV structure and function, and hemodynamic characteristics"><entity charOffset="47-57" id="DDI-PubMed.26401256.s3.e0" text="ranolazine" /><entity charOffset="88-97" id="DDI-PubMed.26401256.s3.e1" text="PAH" /><pair ddi="false" e1="DDI-PubMed.26401256.s3.e0" e2="DDI-PubMed.26401256.s3.e0" /><pair ddi="false" e1="DDI-PubMed.26401256.s3.e0" e2="DDI-PubMed.26401256.s3.e1" /></sentence><sentence text=" We therefore conducted a 3-month, prospective, open-label pilot study involving patients with symptomatic PAH (n = 11) and echocardiographic evidence of RV dysfunction"><entity charOffset="107-109" id="DDI-PubMed.26401256.s4.e0" text="PAH" /></sentence><sentence text=" We evaluated the safety and tolerability of ranolazine and compared symptoms, exercise capacity, exercise bicycle echocardiographic parameters, and invasive hemodynamic parameters between baseline and 3 months of ranolazine therapy using paired t tests"><entity charOffset="45-55" id="DDI-PubMed.26401256.s5.e0" text="ranolazine" /><entity charOffset="214-224" id="DDI-PubMed.26401256.s5.e1" text="ranolazine" /><pair ddi="false" e1="DDI-PubMed.26401256.s5.e0" e2="DDI-PubMed.26401256.s5.e0" /><pair ddi="false" e1="DDI-PubMed.26401256.s5.e0" e2="DDI-PubMed.26401256.s5.e1" /></sentence><sentence text=" Of the 11 patients enrolled, one discontinued ranolazine therapy due to a drug-drug interaction after 3 days of therapy"><entity charOffset="47-57" id="DDI-PubMed.26401256.s6.e0" text="ranolazine" /></sentence><sentence text=" All 10 of the remaining patients continued therapy for 3 months, and 8 (80%) of 10 completed all study tests" /><sentence text=" After 3 months, ranolazine administration was safe and associated with improvement in functional class (P = 0"><entity charOffset="17-27" id="DDI-PubMed.26401256.s8.e0" text="ranolazine" /></sentence><sentence text="0013), reduction in RV size (P = 0" /><sentence text="015), improved RV function (improvement in RV strain during exercise at 3 months; P = 0" /><sentence text="037), and a trend toward improved exercise time and exercise watts on bicycle echocardiography (P = 0" /><sentence text="06 and 0" /><sentence text="01, respectively)" /><sentence text=" Ranolazine was not associated with improvement in invasive hemodynamic parameters"><entity charOffset="1-11" id="DDI-PubMed.26401256.s14.e0" text="Ranolazine" /></sentence><sentence text=" In conclusion, in a pilot study involving PAH, ranolazine therapy was safe and well tolerated, and it resulted in improvement in symptoms and echocardiographic parameters of RV structure and function but did not alter invasive hemodynamic parameters"><entity charOffset="48-58" id="DDI-PubMed.26401256.s15.e0" text="ranolazine" /><entity charOffset="43-52" id="DDI-PubMed.26401256.s15.e1" text="PAH" /><pair ddi="false" e1="DDI-PubMed.26401256.s15.e1" e2="DDI-PubMed.26401256.s15.e1" /><pair ddi="false" e1="DDI-PubMed.26401256.s15.e1" e2="DDI-PubMed.26401256.s15.e0" /></sentence><sentence text=" ClinicalTrials" /><sentence text="gov Identifier: NCT01174173" /><sentence text=" " /></document>